Washington, DC, United States of America

Pan Zheng

This inventor holds 30 USPTO granted patents and 25 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Immunotherapy Research. Top assignees: Oncoimmune, Inc., Oncoc4, Inc., Children's National Medical Center. Active years: 2005-2026.

USPTO Granted Patents = 30 (Patent Applications = 25)

% Patents Active = 76.7

CIPO Patents = 4 (Patent Applications = 19)

EPO Patents = 10 (Patent Applications = 30)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Columbus, OH (US) (2005 - 2010)
Ann Arbor, MI (US) (2012 - 2017)
Potomac, MD (US) (2021)
Washington, DC (US) (2017 - 2023)
Baltimore, MD (US) (2024)

Company Filing History:

Children's National Medical Center

patents

4. 3 out of 1,575

The Ohio State University

patents

5. 3 out of 3,523

University of Michigan

patents

6. 3 out of 2,023

University System of Maryland

patents

7. 2 out of 7

Children's Research Institute, Children's National Medical Center

9. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

CD24 Interactions

CTLA4 Antibodies

Liver Fibrosis

Leukemia Relapse

Lupus Nephritis

Rheumatoid Arthritis

Hypoxia-Inducible Factors

T-Cell Destruction

Drug-Related Side Effects

FOXP3 Tumor Suppression

Monoclonal Antibodies

Binding Protein Compositions

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697369 - Targeting CD24-Siglec Interactions for the Treatment of nonviral hepatitis and liver fibrosis (2026-08-04),

2. 12473362 - Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof (2025-11-18),

3. 12441780 - CD80 and CD86 binding protein compositions and uses thereof (2025-10-14),

4. 12286485 - Anti-CD24 compositions and uses thereof (2025-04-29),

5. 12227557 - CD80 and CD86 binding protein compositions and uses thereof (2025-02-18),

6. 12129299 - Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects (2024-10-29),

7. 11911441 - Methods of use of CD24 for the prevention and treatment of leukemia relapse (2024-02-27),

8. 11629188 - Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof (2023-04-18),

9. 11571461 - Methods of use of soluble CD24 for treating lupus nephritis (2023-02-07),

10. 11547741 - Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies (2023-01-10),

11. 11261233 - CD80 and CD86 binding protein compositions and uses thereof (2022-03-01),

12. 11116726 - Echinomycin formulation, method of making and method of use thereof (2021-09-14),

13. 11026995 - Use of CD24 for lowering low-density lipoprotein cholesterol levels (2021-06-08),

14. 10799558 - Use of CD24 proteins for treating leptin-deficient conditions (2020-10-13),

15. 10793617 - Methods of use of soluble CD24 for therapy of rheumatoid arthritis (2020-10-06),

Title: The Innovative Mind of Pan Zheng

Introduction: Pan Zheng is a pioneering inventor based in Washington, DC, known for her groundbreaking contributions to various fields.

Latest Patents: Pan Zheng's most recent patents include advancements in renewable energy technology, medical devices, and artificial intelligence systems.

Career Highlights: With a career spanning over two decades, Pan Zheng has established herself as a leading figure in the innovation landscape. Her work has led to numerous patents and innovations that have significantly impacted industries worldwide.

Collaborations: Pan Zheng has collaborated with top research institutions, universities, and companies to further develop and implement her inventions. Her collaborative efforts have resulted in cutting-edge solutions that address complex challenges.

Conclusion: Pan Zheng's dedication to innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.